Emergency management and nursing care of a patient with moxifloxacin-induced anaphylactic shock complicated with Takotsubo syndrome.
- 1Department of General Internal Medicine, Zhejiang Provincial Tongde Hospital, Hangzhou, Zhejiang, 320012, China.
- 2Department of Nursing, Zhejiang Provincial Tongde Hospital, Hangzhou, Zhejiang, 320012, China. [email protected].
- 3Department of Cardiovascular, Zhejiang Provincial Tongde Hospital, Hangzhou, Zhejiang, 320012, China.
Abstract
Background
Takotsubo syndrome (TTS) is an acute cardiac condition marked by reversible left ventricular dysfunction, with clinical features that resemble acute coronary syndrome but occur without significant coronary artery stenosis. Its development is strongly linked to catecholamine-mediated toxicity. Inflammatory mediators released during allergic responses may further amplify catecholamine secretion; however, drug-induced anaphylactic shock accompanied by TTS has only been rarely documented.Case presentation
A 31-year-old female experienced simultaneous anaphylactic shock and TTS (EF 31%) after receiving intravenous moxifloxacin. Emergency management involved adrenaline, corticosteroids, and antihistamines, together with PICCO-guided circulatory support (target MAP ≥ 65 mmHg) and combined antiplatelet/anticoagulant therapy. A family-based "3-min emergency response" training program and a graded rehabilitation protocol were carried out. Before discharge, ADRB1 genetic testing was completed, which identified the GG genotype, and beta-blocker treatment was then started accordingly. The patient's EF increased to 45% within 48 h, recovered completely within 10 days, and remained stable throughout 6-month pregnancy follow-up under multidisciplinary care, including dynamic EF monitoring ≥ 55% and anticoagulant adjustment.Conclusion
Moxifloxacin may contribute to TTS through allergic-sympathetic pathways, making careful recognition of overlapping symptoms necessary. Important approaches for lowering recurrence risk include family training, gene-guided therapy, and multidisciplinary cooperation. This study offers useful insight into the care of drug-related TTS, highlighting the need for allergy assessment before drug administration and continued follow-up care. This study was approved by the Medical Ethics Committee of Zhejiang Provincial Tongde Hospital (Ethics Approval No: 2025-Research-069), and the patient provided written informed consent for the use of anonymized case data for academic research.Clinical trial number
MR-33-25-027765.
Related
- Reverse Takotsubo Cardiomyopathy Complicated by Neurogenic Pulmonary Edema in Aneurysmal Subarachnoid Hemorrhage: A Case Report.
- Pregnancy Complicated by Citrin Deficiency and Gestational Diabetes Mellitus: Perioperative Metabolic Management and Postoperative Analgesic Challenges Following Caesarean Delivery
- Endoscopic Management of Bouveret Syndrome Complicated by Jejunal Perforation.
- Effects of Psycho-Cardiology Model-Based Psychological and Behavioural Management on Negative Emotions and Sleep Disorders in Patients With Resistant Hypertension Complicated by Anxiety and Depression
- Conservative Management of a Complicated Crown Fracture Using Autogenous Fragment Reattachment and Fiber Reinforcement: A Case Report
BibTeX
@article{jiang2026emergency,
title = {{Emergency management and nursing care of a patient with moxifloxacin-induced anaphylactic shock complicated with Takotsubo syndrome.}},
author = {Shuqing Jiang and Aihua Jiang and Yongjun Ying and Chunxia Chen and Xian Tian and Xialing Dai},
journal = {BMC cardiovascular disorders},
year = {2026},
month = aug,
doi = {10.1186/s12872-026-06264-z},
url = {https://europepmc.org/article/MED/42972246},
note = {CC BY},
}
RIS
TY - JOUR
TI - Emergency management and nursing care of a patient with moxifloxacin-induced anaphylactic shock complicated with Takotsubo syndrome.
AU - Shuqing Jiang
AU - Aihua Jiang
AU - Yongjun Ying
AU - Chunxia Chen
AU - Xian Tian
AU - Xialing Dai
PY - 2026
DA - 2026/08/06
JO - BMC cardiovascular disorders
DO - 10.1186/s12872-026-06264-z
UR - https://europepmc.org/article/MED/42972246
AB - Background Takotsubo syndrome (TTS) is an acute cardiac condition marked by reversible left ventricular dysfunction, with clinical features that resemble acute coronary syndrome but occur without significant coronary artery stenosis. Its development is strongly linked to catecholamine-mediated toxicity. Inflammatory mediators released during allergic responses may further amplify catecholamine secretion; however, drug-induced anaphylactic shock accompanied by TTS has only been rarely documented.Case presentation A 31-year-old female experienced simultaneous anaphylactic shock and TTS (EF 31%) after receiving intravenous moxifloxacin. Emergency management involved adrenaline, corticosteroids, and antihistamines, together with PICCO-guided circulatory support (target MAP ≥ 65 mmHg) and combined antiplatelet/anticoagulant therapy. A family-based "3-min emergency response" training program and a graded rehabilitation protocol were carried out. Before discharge, ADRB1 genetic testing was completed, which identified the GG genotype, and beta-blocker treatment was then started accordingly. The patient's EF increased to 45% within 48 h, recovered completely within 10 days, and remained stable throughout 6-month pregnancy follow-up under multidisciplinary care, including dynamic EF monitoring ≥ 55% and anticoagulant adjustment.Conclusion Moxifloxacin may contribute to TTS through allergic-sympathetic pathways, making careful recognition of overlapping symptoms necessary. Important approaches for lowering recurrence risk include family training, gene-guided therapy, and multidisciplinary cooperation. This study offers useful insight into the care of drug-related TTS, highlighting the need for allergy assessment before drug administration and continued follow-up care. This study was approved by the Medical Ethics Committee of Zhejiang Provincial Tongde Hospital (Ethics Approval No: 2025-Research-069), and the patient provided written informed consent for the use of anonymized case data for academic research.Clinical trial number MR-33-25-027765.
SN - 1471-2261
ER -